Recent News

• 06.13.2025 - Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
• 06.13.2025 - Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
• 06.11.2025 - Virtual Annual Meeting of Stockholders
• 06.11.2025 - Virtual Annual Meeting of Stockholders
• 05.14.2025 - Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
• 05.14.2025 - Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
• 05.05.2025 - Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
• 05.05.2025 - Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
• 04.01.2025 - Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.13.2025 - 8-K Current report
• 05.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.05.2025 - EX-99.1 EX-99.1
• 05.05.2025 - 8-K Current report
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - DEF 14A Other definitive proxy statements